Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:ENGNNASDAQ:FATENASDAQ:GRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.54-1.2%$1.87$0.91▼$6.05$215.14M2.152.61 million shs2.14 million shsENGNenGene$3.81+0.3%$3.61$2.65▼$11.00$194.20M-0.42127,734 shs73,984 shsFATEFate Therapeutics$1.06-5.4%$1.21$0.66▼$5.92$128.36M2.182.23 million shs1.30 million shsGRNAGreenLight Biosciences$0.30$0.30$0.18▼$5.90$45.43M1.44486,986 shs732 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine0.00%+13.38%+35.34%+158.50%-43.68%ENGNenGene0.00%+6.01%+2.65%-17.09%-57.60%FATEFate Therapeutics0.00%+10.10%-28.44%+25.91%-63.88%GRNAGreenLight Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.1694 of 5 stars3.23.00.04.32.02.50.6ENGNenGene2.7698 of 5 stars3.53.00.00.01.52.50.6FATEFate Therapeutics4.2431 of 5 stars3.13.00.04.73.21.70.6GRNAGreenLight BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.31Hold$4.7085.04% UpsideENGNenGene 3.00Buy$23.29511.17% UpsideFATEFate Therapeutics 2.13Hold$3.83261.64% UpsideGRNAGreenLight Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRNA, FATE, EDIT, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M6.58N/AN/A$1.63 per share1.56ENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AFATEFate Therapeutics$13.63M8.91N/AN/A$2.80 per share0.38GRNAGreenLight Biosciences$10.20M4.45N/AN/A$0.32 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)ENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/AFATEFate Therapeutics-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)GRNAGreenLight Biosciences-$167.05M-$1.14N/A∞N/A-1,521.00%-374.26%-122.78%N/ALatest GRNA, FATE, EDIT, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/A5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AGRNAGreenLight BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.083.08ENGNenGene0.0912.6612.66FATEFate TherapeuticsN/A8.818.81GRNAGreenLight Biosciences0.491.211.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%ENGNenGene64.16%FATEFate Therapeutics97.54%GRNAGreenLight Biosciences24.41%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%ENGNenGene10.40%FATEFate Therapeutics5.51%GRNAGreenLight Biosciences30.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million82.12 millionOptionableENGNenGene3151.10 million45.79 millionN/AFATEFate Therapeutics550114.60 million108.29 millionOptionableGRNAGreenLight Biosciences280151.68 million105.72 millionNot OptionableGRNA, FATE, EDIT, and ENGN HeadlinesRecent News About These CompaniesGreenLight Bio closes Series C with $25M from Just ClimateApril 3, 2025 | ncbiotech.orgNScaling RNA Technology for Sustainable Crop ProtectionDecember 20, 2024 | agribusinessglobal.comAEU states greenlight extra tariffs on EVs from ChinaOctober 6, 2024 | france24.comFGreenlight AutoMay 23, 2024 | cars.comCGreenlight Promo CodesMay 11, 2024 | wired.comWGreenlight Coupon CodesApril 21, 2024 | washingtonpost.comSaudi Arabia gives green light to Paraguayan meat exportsJanuary 6, 2024 | en.mercopress.comEGreenLight Biosciences Secures U.S. EPA Registration for New BioinsecticideJanuary 5, 2024 | agribusinessglobal.comASplashdown Quaywest gets green light for £3m upgradeDecember 20, 2023 | bbc.comBEnergy companies get green light to drill EnvironmentOctober 9, 2023 | iol.co.zaIBroadwalk Shopping Centre redevelopment given green lightSeptember 28, 2023 | bbc.comBKenya urges quick UN green light of Haiti missionSeptember 25, 2023 | france24.comFGreenlight Family Cash Card 2023 ReviewSeptember 19, 2023 | forbes.comGreen Light LEGO, Red Light StopAugust 20, 2023 | hackaday.comHGreenLight Biosciences: GreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 24, 2023 | finanznachrichten.deGreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 24, 2023 | finance.yahoo.comGreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding SharesJuly 20, 2023 | finance.yahoo.comGreenLight Bio Sued by Investors Eyeing Venture Capital SaleJuly 19, 2023 | news.bloomberglaw.comNRNA company to lay off 96 employees in LexingtonJune 13, 2023 | bizjournals.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRNA, CIR, REUNJune 11, 2023 | bakersfield.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockCapitalize on Volatility: 3 Finance Stocks Thriving in 2025By Chris Markoch | July 2, 2025View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025GRNA, FATE, EDIT, and ENGN Company DescriptionsEditas Medicine NASDAQ:EDIT$2.54 -0.03 (-1.17%) Closing price 04:00 PM EasternExtended Trading$2.54 0.00 (-0.20%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.enGene NASDAQ:ENGN$3.81 +0.01 (+0.26%) Closing price 04:00 PM EasternExtended Trading$3.79 -0.02 (-0.52%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Fate Therapeutics NASDAQ:FATE$1.06 -0.06 (-5.36%) Closing price 04:00 PM EasternExtended Trading$1.07 +0.01 (+0.85%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.GreenLight Biosciences NASDAQ:GRNAFUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
